Comparison of biochemical safety between PEG-IFN a-2a and peg-ifn α-2b

Hepato-Gastroenterology

Volumn 56, Issue 90, 2009, Pages 485-491

  Katano, Yoshiaki ^a   Kumada, Takashi ^b   Nakano, Isao ^a   Toyoda, Hidenori ^b   Ishigami, Masatoshi ^a   Hayashi, Kazuhiko ^a   Honda, Takashi ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Blood cell; Chronic hepatitis C; Pegylated interferon; Ribavirin

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MALE; NEUTROPHIL COUNT; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LEUKOCYTE COUNT; LINEAR MODELS; MALE; MIDDLE AGED; PLATELET COUNT; POLYETHYLENE GLYCOLS; RIBAVIRIN; SAFETY; STATISTICS, NONPARAMETRIC;

EID: 67649213187     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon plus ribavirin for initial treat- ment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu Ji Peginterforon ulfa-2a plus ribavirin for chrome hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group: Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Internal Med 2004; 140:346-355.
4. lino S, Okita K, Omata M, Kumada H, Hayashi N, 'Tanikawa K: Efficacy of 48-week combined PEG-interfer-on a-2b + ribavirin therapy in chronic hepatitis C with genotype I and high virus level - A retrospective compari- son with 6-month combined interferon a-2b + ribavirin. Kan Tan Sui (Japanese) 2004; 49:1099-1121.
5. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanches-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J: Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatology 2004; 40:993-999.
6. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Pérsico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A: Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Eng J Med 2005; 3523609-2617.
7. Von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S: Peginterferon- a-2a(40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
8. Kumada H, Toyota J, Goto K, Imawari M, Fujiwara K, Yokosuka O, Sato N, Yasuda K, Izumi N, Ichida T, Honda M, Koj ima K, Yoshioka K, Tomita E, Kumada T, Kato M, Yoshihara H, Shimomura H, Yamada G, Sakisaka S, Tanikawa K: Efficacy of 24-week combined PEG-interferon a-2b + ribavirin therapy in chronic hepatitis C cases with genotype I and low virus level and genotype 2 chronic hepatitis C cases - A comparison with 24-weeek combined interferon a-2b + ribavirin. Kan Tan Sui (Japan- eses) 2006; 52:645-663.
9. Meta-analysis Working Group: Efficacy of PEG-IFN alfa-2b vs. PEG-IFN alfa-2a+ ribavirin regimens in treatment-naive chronic HCV patients: a cumulative meta analysis of retrospective data from 6 clinic sites. Hepatology 2005; 42(Suppl. 1):671A.
10. Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, Ferenci P, Peck-Radosavljevic M: Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon a mono and combination thera- py regimens. Gut 2005; 54:1014-1120.
11. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Ciappina V, Patruno S, Filice G: Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naïve patients with chronic hepatitis C. Antiviral Therapy 2005; 10:201-205.
12. Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, Bordens R, Cullen C, Harvey J, Laughlin M: A randomised trial to compare the pharmacokinetic, pharmaco-dynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatology 2006; 45:204-213.
13. Toyota J, Karino Y, Akaike J, Ohmura T, Sato T, Yamazaki K, Kuwata Y, lino S: Systemic ribavirin clearance (CIVF) is the factor most closely related to dose reduction and discontinuation of drug therapy for a reason of complication by anemia. Acta Hepatologica Japonica (Japanese) 2005; 46:107-118.
14. Maeda Y, Kiribayashi Y, Moriya T, Maruhashi A, Omoda K, Funakoshi S, Murakami T, Takáno M: Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004; 26:9-15.
15. Donnerer J, Grahovac M, Stelzl E, Kessler HH, Bankuti C, Stadbauer V, Stauber RE: Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology 2006; 76:136-140.
16. Kowdley KV:. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39(suppl. 1):S3-S8.
17. Kuboki M, lino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T: Peginterferon a-2a -40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007; 22:645-652.
18. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L: Ribavirin pharmacokinetics in renal and liver transplantation patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43:140-146.
19. Bruno S, Cammà C, Di Marco V, Rumi M, Vinci M, Camozzi M, Rebucei C, Di Bona D, Colombo M, Craxi A, Mondelli MU, Pinzello G: Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatology 2004; 41:474-481.
20. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S: Pegylated interferon- a2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol & Therapy 2000; 68:556-567.
21. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J: Pegin terferon alfa-2a in patients with chronic hepatitis C and cir- rhosis. New Engl J Med 2000; 343:1673-1680.
22. Lurie Y, Rouzier-Panis R, Webster GJ, Dusheiko GM, Laughlin M, Jackson ML, Oren R: Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection. Clinical Gastroenterol and Hepatol. 2005; 3:610-615.
23. Tsubota A, Hirose Y, Izumi N, Kumada H: Pharmaco-kinetics of ribavirin in combined interferon alpha-2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003; 55:360-367.
24. Juarez-Navarro A, Vera-de-Leon L, Navarro JM, Chirino-Sprung R, Diaz-Hernandez M, Casillas-Davi- Ia L, Dehesa-Violante M: Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-a2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol 2005; 27:317-322.
25. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.